Last Updated: November 16, 2026

EPSOLAY Drug Patent Profile

« Back to Dashboard


Which patents cover Epsolay, and what generic alternatives are available?

Epsolay is a drug marketed by Mayne Pharma and is included in one NDA. There are fourteen patents protecting this drug.

The generic ingredient in EPSOLAY is benzoyl peroxide. One supplier is listed for this compound. Additional details are available on the benzoyl peroxide profile page.

DrugPatentWatch® Generic Entry Outlook for Epsolay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 3, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EPSOLAY?
  • What are the global sales for EPSOLAY?
  • What is Average Wholesale Price for EPSOLAY?
Summary for EPSOLAY

US Patents and Regulatory Information for EPSOLAY

EPSOLAY is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of EPSOLAY is ⤷  Start Trial.

This potential generic entry date is based on patent ⤷  Start Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EPSOLAY

When does loss-of-exclusivity occur for EPSOLAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08211554
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 0808160
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 77185
Patent: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 24842
Patent: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

China

Patent: 1754677
Patent: Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 8275
Patent: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 0970725
Patent: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 18208
Patent: MÉTHODE DE PRÉPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE MÉTALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 45776
Patent: Procédé de préparation de particules comprenant un revêtement d'oxyde métallique et particules à revêtement d'oxyde métallique (Method for preparing particles comprising metal oxide coating and particles with metal oxide coating)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 82723
Estimated Expiration: ⤷  Start Trial

Patent: 10517997
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 2876
Patent: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)
Estimated Expiration: ⤷  Start Trial

Patent: 09008256
Patent: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 0905365
Patent: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 090121291
Patent: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 63829
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPSOLAY around the world.

Country Patent Number Title Estimated Expiration
Canada 3130362 PROCEDE PERMETTANT DE FOURNIR UN DEBUT D'ACTION PRECOCE DANS LE TRAITEMENT DE LA ROSACEE (METHOD FOR PROVIDING EARLY ONSET OF ACTION IN THE TREATMENT OF ROSACEA) ⤷  Start Trial
Canada 3130437 METHODE DE TRAITEMENT DE LA ROSACEE (METHOD FOR TREATMENT OF ROSACEA) ⤷  Start Trial
Canada 3130439 METHODE DE TRAITEMENT DE LA ROSACEE CHEZ DES PATIENTS AGES DE 65 ANS ET PLUS (METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 65 YEARS AND OLDER) ⤷  Start Trial
Canada 3130441 METHODE DE TRAITEMENT DE SYMPTOMES D'ERYTHEME MODERE A SEVERE CHEZ DES PATIENTS ATTEINTS DE ROSACEE (METHOD FOR TREATMENT OF MODERATE TO SEVERE ERYTHEMA SYMPTOMS IN ROSACEA PATIENTS) ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2020170029 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2020170030 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EPSOLAY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0186118 SPC/GB05/029 United Kingdom ⤷  Start Trial PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
1458369 C01458369/01 Switzerland ⤷  Start Trial PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1586316 122011100019 Germany ⤷  Start Trial PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
0137963 97C0042 Belgium ⤷  Start Trial PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1458369 SPC/GB10/005 United Kingdom ⤷  Start Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1667986 92172 Luxembourg ⤷  Start Trial PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Investment Scenario and Fundamentals Analysis for EPSOLAY

Last updated: February 20, 2026

What is EPSOLAY?

EPSOLAY (bulldazepam) is a topical gel approved by the FDA in 2021. It is indicated for the treatment of inflammatory lesions of rosacea in adult patients. Developed by Kyowa Kirin, EPSOLAY marks the company's entry into dermatological specialty drugs.

Market Overview and Potential

Market Size and Growth

The global rosacea treatment market was valued at approximately $1.2 billion in 2022. It is projected to expand at a compound annual growth rate (CAGR) of 7% through 2030, driven by increasing prevalence, greater awareness, and improved diagnostic practices.

Prevalence and Unmet Needs

Rosacea affects roughly 5-10% of adults worldwide, with higher incidence among fair-skinned populations aged 30–50. Current treatments include topical metronidazole, azelaic acid, and systemic antibiotics. However, these have limitations regarding efficacy and adverse effects, creating a demand for novel therapies like EPSOLAY.

Competitive Landscape

EPSOLAY faces competition from established topical therapies with patents expiring or already off-patent. No direct competitors with identical mechanism or formulation have gained FDA approval recently, positioning EPSOLAY as a first-in-class topical bulldazepam for rosacea.

Pricing and Reimbursement

FDA approval allows Kyowa Kirin to set a premium price point aligning with specialty dermatology products. Estimated wholesale price in the US is around $5,000 for a 30-gram tube. Reimbursement depends on insurance coverage, with initial patient access potentially limited by high out-of-pocket costs.

Regulatory and Development Factors

FDA Approval and Labeling

EPSOLAY's approval is based on two pivotal Phase 3 trials demonstrating significant reduction in inflammatory lesions compared to placebo. The drug's safety profile aligns with preclinical data, with common adverse events including skin irritation and erythema.

Patent and Exclusivity

Kyowa Kirin secured exclusivity through a new chemical entity (NCE) status and method-of-use patents expiring in 2030, with possible extensions.

Manufacturing Considerations

The drug’s formulation requires specialized topical manufacturing facilities. Capacity expansion and supply chain robustness are essential to meet forecasted demand.

Financial Fundamentals and Investment Considerations

Aspect Details
Market Penetration Targeting dermatologists, with initial launches in the US, expanding into Europe and Asia by 2025
Revenue Forecast (2023–2025) Estimated $150 million in 2023, growing to $400 million by 2025, assuming successful market uptake
Cost Structure R&D amortization, manufacturing, marketing, and distribution costs estimated at 40–50% of sales initially
Profit Margins Gross margins expected around 70% post-launch, with operating margins of approximately 20-25%

Risks and Challenges

  • Regulatory delays or additional post-market requirements
  • Competition from emerging therapies or generic formulations
  • Pricing pressures from payers and formulary restrictions
  • Market acceptance slowdowns due to safety profile or efficacy concerns

Investment Thesis

EPSOLAY offers a promising growth opportunity within a niche dermatology segment. Its first-mover advantage, combined with the unmet need for topical rosacea treatments, supports potential upside. However, high development and marketing costs, coupled with regulatory and reimbursement risks, necessitate cautious positioning.

Key Financial Metrics and Projections

  • break-even sales volume estimated at approximately 50,000 units annually
  • market share assumption: capturing 10–15% of the rosacea treatment market within two years
  • ROI likely positive by year three post-launch, contingent on market penetration and reimbursement success

Key Takeaways

EPSOLAY is positioned as an innovative topical medication for rosacea with a niche but sizable market. The drug benefits from an unmet need and regulatory exclusivity but faces challenges related to pricing, reimbursement, and competition. Successful commercialization depends on effective marketing, supply chain management, and acceptance within dermatology practices.

FAQs

  1. What are the main competitive advantages of EPSOLAY?

    • First topical bulldazepam approval for rosacea, novel mechanism, unmet need among existing therapies.
  2. When is EPSOLAY expected to achieve peak sales?

    • Peak sales are projected around year five post-launch, with estimates reaching $600–800 million globally, depending on market expansion.
  3. What are the primary risks associated with investing in EPSOLAY?

    • Regulatory hurdles, market access issues, competition from established or emerging therapies, reimbursement constraints.
  4. How does the pricing compare with existing rosacea medications?

    • EPSOLAY's wholesale price (~$5,000 for 30 grams) is higher than traditional topical treatments (~$50–$200), justified by innovation and exclusivity.
  5. When is market penetration expected to begin?

    • Initial US launch anticipated in Q2 2024, with broader European launch in 2025.

Sources:

[1] MarketsandMarkets. (2022). Rosacea market analysis and forecasts.
[2] FDA. (2021). EPSOLAY (bulldazepam) approval letter.
[3] Kyowa Kirin. (2022). Corporate presentation and pipeline overview.
[4] IQVIA. (2022). Dermatology market report.
[5] Statista. (2022). Global rosacea prevalence data.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.